New Online Resource Launches For Patients With Chronic Myeloid Leukemia
Many people living with cancer are researching their illnesses online. In fact, research has shown that patients who use the Internet consider it a more useful source of information as compared with other media. Further, patients' Internet use can encourage active communication with their physicians. These are the reasons why, Bristol-Myers Squibb Company (NYSE:BMY) is making available a new comprehensive Web site called MyCMLCare.com for patients with chronic myeloid leukemia (CML) and their caregivers. 
Boehringer Ingelheim announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for Viramune® (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA) who reviewed the clinical evidence and approved a statement in the SmPC recognising the positive effect of nevirapine on the lipid profile of HIV infected patients.
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. 
AstraZeneca announced that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy. 
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced a collaboration to develop macrophage-targeted compounds using Chroma's proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.